~~<i id='6F695A32F2'><strike id='6F695A32F2'><tt id='6F695A32F2'><pre id='6F695A32F2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

focus

author：Wikipedia 2025-10-01 01:00:38 - browse：2

WASHINGTON — Back in 1980, when the Food and Drug Administration approved the use of lead acetate in hair dyes, little was known about the way skin absorbs toxic chemicals.

The skin — and the scalp in particular — were considered tough barriers to break, and many public health officials believed that even if small amounts of lead got through, or were inhaled, it couldn’t really hurt anyone.

But in science, 37 years is an eon. So a coalition of environmental groups, academics, and consumer advocates is pushing FDA to take lead acetate off the market. It is now permitted as a color additive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： This gene therapy has record $4.25 million price. It's saved children.

knowledge

entertainment

knowledge

hotspot

leisure time

ScientistFengZhang,right,isinterviewedbyreporterMeganMolteniatSTAT'sBreakthroughSummitEast.STATWhent

WSS

Testing GLP

Asbestos ban is immediate, but health effects will linger for decades

Adam's Take: Intra

Steward Health Care expansion into Malta flopped

CRISPR technology availability, affordability needs to be expanded

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

knowledge

focus

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Decaf coffee targeted by food safety group under obscure FDA rule

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout LOUD podcast: mifepristone case, GLP

Jerome Adams on the need for new antivirals for Covid

This gene therapy has record $4.25 million price. It's saved children.

Peter Hotez and the public health issue of online harassment

Mirador, a new biotech startup, launches with $400 million

Cancer drug shortages should be causing more outrage

Supreme Court mifepristone arguments center on docs' right to sue

knowledge

Abortion pill Supreme Court ruling could impact entire drug industry

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Diabetes management: Digital health tools fall short, study says

Patient advocates debate FDA's accelerated approval process

Abortion pill case raises question: who can sue the FDA?

entertainment

knowledge

hotspot

leisure time